Publications
-
- Conference presentation
- [ADA 2021] DA-1241 a novel GPR119 Agonist Data on Safety, Tolerability and Pharmacokinetics(PK), from Part 1 of a Phase 1b Multiple Ascending Dose(MAD) Study in Healthy Volunteers(HV)
-
- Conference presentation
- [ADA 2021] DA-1241 a novel GPR119 Agonist: Data on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics from Part 2 of a Phase 1b Multiple Ascending Dose Study in Patients with Type 2 Diabetes Mellitus
-
- Paper publication
- A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects. Drug Des Devel Ther. 2023 Apr 21;17:1203-1210. doi: 10.2147/DDDT.S404182. PMID: 37113469; PMCID: PMC10128151.Kim HC, Lee S, Sung S, Kim E, Jang IJ, Chung JY.
-
- Paper publication
- Synthesis and Evaluation of Dapagliflozin Ester Prodrugs with Improved Hygroscopicity and Thermal Stability. Letters in Drug Design & Discovery, Volume 17, Number 11, 2020, pp. 1409-1421(13) . doi: 10.2174/1570180817999200618162949 Sung SY, Chae YN, Lee DY, Kim KM, Kim EJ, Han JH, Kim WY, Sung-Hwa.
-
- Paper publication
- Absorption, metabolism, and excretion of [14C]evogliptin tartrate in male rats and dogs. J Toxicol Environ Health A. 2018;81(11):453-464. doi: 10.1080/15287394.2018.1451194. Epub 2018 Mar 20. PMID: 29557727.Lee DY, Kim JH, Shim HJ, Jeong HU, Lee HS.
-
- Paper publication
- Additive effects of evogliptin in combination with pioglitazone on fasting glucose control through direct and indirect hepatic effects in diabetic mice. Eur J Pharmacol. 2018 Jul 5;830:95-104. doi: 10.1016/j.ejphar.2018.04.033. Epub 2018 May 1. PMID: 29727638. Kim TH, Lee JH, Chae YN, Jung IH, Kim MK.
-
- Paper publication
- Unique binding mode of Evogliptin with human dipeptidyl peptidase IV. Biochem Biophys Res Commun. 2017 Dec 16;494(3-4):452-459. doi: 10.1016/j.bbrc.2017.10.101. Epub 2017 Oct 20. PMID: 29061303. Lee HK, Kim MK, Kim HD, Kim HJ, Kim JW, Lee JO, Kim CW, Kim EE.
-
- Paper publication
- In vitro evaluation of potential transporter-mediated drug interactions of evogliptin. Biopharm Drug Dispos. 2017 Sep;38(6):398-403. doi: 10.1002/bdd.2083. Epub 2017 Jul 13. PMID: 28503751.Lee DY, Chae HW, Shim HJ.
-
- Paper publication
- Bioanalytical validation for the determination of evogliptin and its metabolites m7/m8 in human plasma by liquid chromatography-tandem mass spectrometry. Drug Metab Pharmacokinet. vol. 32,1 (2017): S27. doi.org/10.1016/j.dmpk.2016.10.127 Kyunghee Cho, Sun Koung Joung, Sookie La, Dae Young Lee, Hyun Joo Shim, Ji Su Song, Hee Joo Lee
-
- Paper publication
- Hepatic role in an early glucose-lowering effect by a novel dipeptidyl peptidase 4 inhibitor, evogliptin, in a rodent model of type 2 diabetes. Eur J Pharmacol. 2016 Jan 15;771:65-76. doi: 10.1016/j.ejphar.2015.11.029. Epub 2015 Nov 24. PMID: 26621343.Kim TH, Kim MK, Cheong YH, Chae YN, Lee Y, Ka SO, Jung IH, Shin CY, Bae EJ, Son MH.